ESR1 and breast cancer: The data demonstrated that the targeted polymersomes have the potential to selectively target the ER-positive breast cancer cells, break into the hypoxic niches of the 3D spheroids, release nanoencapsulated doxorubicin, and reduce the MCF-7 breast cancer spheroid growth.